<DOC>
	<DOCNO>NCT03053466</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , recommend dose CBT-501 individual advance relapsed recurrent solid tumor .</brief_summary>
	<brief_title>CBT-501 Study Select Advanced Relapsed/Recurrent Solid Tumors</brief_title>
	<detailed_description>This Phase 1 , multicenter , 2-part study Dose-Escalation Segment Dose Disease Expansion Cohort CBT-501 injection , humanize IgG4 monoclonal antibody , target Programmed Death-1 ( PD-1 ) membrane receptor T lymphocytes cell immune system . Select advance solid tumor malignancy receive escalate dos CBT-501 . Dose escalation occur three subject cohort protocol define dose limited toxicity ( DLT ) occur , due disease progression inter-current illness , tentative maximum tolerate dose ( MTD ) determine . At tentative MTD recommend Phase 2 dose ( RP2D ) , least two tumor type assess evaluate toxicity preliminary efficacy .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Major Able understand comply study procedure , understand risk involve , provide write informed consent Histologically / cytological confirm solid tumor : colorectal , endometrial , gastric include , gastroesophageal junction adenocarcinoma ( GC ) , head neck ( esophageal , nasopharyngeal ) , hepatocellular ( HCC ) , nonsmall cell lung cancer , mesothelioma , ovarian , renal cell carcinoma ( RCC ) , either refractory relapsed standard therapy effective standard therapy available . No restriction number prior therapy Dose Escalation Segment Receive three systemic prior therapy Dose Disease Expansion Cohorts Tumor biopsy study entry therapy Measurable disease accord RECIST v1.1 Major History severe hypersensitivity mAbs , excipients drug product component Prior malignancy active within previous 2 year except locally curable cancer cure , basal squamous cell skin cancer , superficial bladder cancer carcinoma situ cervix breast Any active autoimmune disease document history autoimmune disease , history syndrome require systemic steroid immunosuppressive medication , except subject vitiligo resolve childhood asthma/atopy Prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCTLA4 antibody ( antibody target T cell costimulation pathway ) ( except NSCLC ) Symptomatic primary tumor metastasis brain and/or central nervous system , uncontrolled antiepileptic require high dos steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced Solid Tumor</keyword>
	<keyword>Relapsed Solid Tumor</keyword>
	<keyword>Recurrent Solid Tumor</keyword>
</DOC>